Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 combination in HER2-positive advanced breast cancer
NCT07116824Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of albumin-bound docetaxel in HER2-positive breast cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Objective Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
albumin-bound docetaxel
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07116824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116824.